Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Clearside Biomedical Inc (CLSD)

Clearside Biomedical Inc (CLSD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,146
  • Shares Outstanding, K 5,234
  • Annual Sales, $ 1,660 K
  • Annual Income, $ -34,350 K
  • EBIT $ -23 M
  • EBITDA $ -23 M
  • 60-Month Beta 2.04
  • Price/Sales 1.77
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -5.19
  • Most Recent Earnings $-1.14 on 11/14/25
  • Next Earnings Date 03/26/26
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.75
  • Number of Estimates 1
  • High Estimate -0.75
  • Low Estimate -0.75
  • Prior Year -1.50
  • Growth Rate Est. (year over year) +50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3701 +10.78%
on 11/28/25
4.2600 -90.38%
on 11/12/25
-3.4900 (-89.49%)
since 10/28/25
3-Month
0.3701 +10.78%
on 11/28/25
5.7750 -92.90%
on 08/29/25
-5.4010 (-92.94%)
since 08/28/25
52-Week
0.3701 +10.78%
on 11/28/25
17.1000 -97.60%
on 02/07/25
-15.6400 (-97.45%)
since 11/27/24

Most Recent Stories

More News
Clearside Biomedical to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process

- Intended to Maximize Stakeholder Value Through Structured Process - - Validated SCS Microinjector ® Delivery Platform Anchored by Commercial Product and Five Suprachoroidal Licensing Collaborations...

CLSD : 0.4100 (-26.96%)
Clearside Biomedical Regains Nasdaq Compliance as of October 2025

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Clearside...

CLSD : 0.4100 (-26.96%)
Clearside Biomedical Announces Multiple Presentations on Suprachoroidal Delivery to be Featured at the 25th EURETINA Congress

- Presentations Highlight the Versatility of Clearside’s SCS Microinjector ® Platform for the Treatment of Multiple Retinal Diseases - - CLS-AX Trial Designs in Wet AMD and Diabetic Retinopathy...

CLSD : 0.4100 (-26.96%)
Clearside Biomedical Announces Approval of XIPERE® Suprachoroidal Treatment for Uveitic Macular Edema in Canada

- XIPERE Now Approved for Use in Multiple Global Markets - - Continued Global Expansion and Validation of Clearside’s Suprachoroidal Space Injection Platform Featuring its Commercially Proven SCS...

CLSD : 0.4100 (-26.96%)
Clearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space (SCS®) Delivery Platform and Promising Ophthalmology Pipeline

- Proven In-Office, Repeatable, Non-Surgical Procedure for the Targeted Delivery of a Wide Variety of Therapies for Serious Retinal Diseases - - CLS-AX Phase 3-Ready Asset with Global Investigator...

CLSD : 0.4100 (-26.96%)
Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2025 Virtual Ophthalmology Forum

CLSD : 0.4100 (-26.96%)
Clearside Biomedical Announces First Quarter 2025 Financial Results and Provides Corporate Update

CLSD : 0.4100 (-26.96%)
Clearside Biomedical Data Featured in Six Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting

CLSD : 0.4100 (-26.96%)
Clearside Biomedical to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025

CLSD : 0.4100 (-26.96%)
Clearside Biomedical to Participate in a Fireside Chat at the Citizens Life Sciences Conference

CLSD : 0.4100 (-26.96%)

Business Summary

Clearside Biomedical, Inc. is a biopharmaceutical company is engaged in developing first-in-class drug therapies to treat blinding diseases of the eye using Clearside proprietary suprachoroidal space(TM) microinjector. Its products include CLS-1001 for the treatment of macular edema associated with non-infectious...

See More

Key Turning Points

3rd Resistance Point 0.7549
2nd Resistance Point 0.6699
1st Resistance Point 0.5400
Last Price 0.4100
1st Support Level 0.3251
2nd Support Level 0.2401
3rd Support Level 0.1102

See More

52-Week High 17.1000
Fibonacci 61.8% 10.7092
Fibonacci 50% 8.7351
Fibonacci 38.2% 6.7609
Last Price 0.4100
52-Week Low 0.3701

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar